Aristopharma Ltd. has launched Bevaris, preparation of Bevacizumab INN 100 mg & 400 mg concentrated solution for IV infusion.
Bevacizumab is a Vascular Endothelial Growth Factor (VEGF) directed at a recombinant humanized monoclonal antibody (mAb) that blocks the VEGF to bind with its receptor VEGFR on the surface of endothelial cells. The prevention of binding VEGF with VEGFR leads to the inhibition of new blood vessel formation known as angiogenesis that feeds the cancer cells. Thus, Bevacizumab stops the growth & metastasis of different types of cancer. Bevacizumab significantly increases OS & PFS in cancer patients when given with chemotherapy.
FR
DE